1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
609FBD7487F7041F5852580CA0067E91C
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-best-practices-managing-advisory-board-meetings-execution-utilization?opendocument
18
19opendocument
2018.205.246.238
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Medical Affairs Medical Affairs Excellence

Best Practices in Managing Advisory Board Meetings: Execution and Utilization

ID: 5452


Features:

11 Info Graphics

9 Data Graphics

45 Metrics

5 Narratives


Pages/Slides: 28


Published: 2017


Delivery Format: Online PDF Document


 

License Options:

close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.

Buy Now

 

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from "Best Practices in Managing Advisory Board Meetings: Execution and Utilization"

STUDY OVERVIEW

Pharmaceutical companies rely on advisory boards to gain commercial and medical insights about their products, both those in development and those already on the market. However, new Sunshine Act reporting requirements have forced the pharma industry to alter how it manages advisory board meetings. To highlight current practices in executing and utilizing advisory boards, consulting leader Best Practices, LLC conducted this study.

The research explores issues around who leads advisory board management, how long it takes to plan and conduct an advisory board meeting, and how feedback is captured and stored. The study also presents narratives from participants on the challenges and best practices of managing advisory boards. Pharma leaders involved in managing advisory boards can use this study to compare their current ad board management practices with those at best-in-class companies.

KEY TOPICS

  • Study Overview
  • Key Findings & Trends
  • Execution Of Advisory Boards
  • Dissemination And Utilization of Feedback
  • Appendix

SAMPLE KEY METRICS


  • What is the approach you use to execute an advisory board?
  • Do you pay advisors to prepare for an ad board meeting?
  • Average number of months from commitment to execution for both single and multi-country advisory boards
  • How do you capture advisory board feedback?
  • Do you have a restriction on sharing feedback from a medical board?
  • Where do you store your feedback?
  • Describe how you disseminate feedback
  • Top challenges for conducting ad boards
  • Top best practices for conducting ad boards

SAMPLE KEY FINDINGS

  • Companies Face Several Challenges When Conducting Advisory Boards: Recruitment of KOLs, attendance of KOLs, getting the correct target audience, involvement of many stakeholders in review and approval process act as major challenges when conducting advisory boards.
  • Understanding Adviser Feedback is Top Best Practice: Across all the participants, the top three best practices related to advisory boards are understanding the feedback (67%), making clear objectives (56%), and having consistency in planning (33%).

METHODOLOGY


This study engaged 12 leaders with direct experience working in the planning of Advisory Boards, with participants representing 12 leading biopharmaceutical companies. About 70% of participants are at the level of director or above.


Industries Profiled:
Pharmaceutical; Biotech; Chemical; Health Care; Biopharmaceutical; Clinical Research; Laboratories


Companies Profiled:
Daiichi Sankyo; Gilead Sciences; Boehringer Ingelheim; Genentech; UCB Pharma; Sanofi; Teva Pharmaceutical Industries Ltd; Pfizer; Shire; ViiV Healthcare


If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.